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Abstract
Introduction
To evaluate unmet clinical need in unselected hypertrophic cardiomyopathy (HCM) patients
to determine the risk of a wide range of subsequent cardiovascular disease endpoints and
safety endpoints relevant for trial design.
Methods
Population based cohort (CALIBER, linked primary care, hospital and mortality records in
England, period 1997–2010), all people diagnosed with HCM were identified and matched
by age, sex and general practice with ten randomly selected people without HCM. Random-
effects Poisson models were used to assess the associations between HCM and cardiovas-
cular diseases and bleeding.
Results
Among 3,290,455 eligible people a diagnosis of hypertrophic cardiomyopathy was found in
4 per 10,000. Forty-one percent of the 1,160 individuals with hypertrophic cardiomyopathy
were women and the median age was 57 years. The median follow-up was 4.0 years. Com-
pared to general population controls, people with HCM had higher risk of ventricular arrhyth-
mia (incidence rate ratio = 23.53, [95% confidence interval 12.67–43.72]), cardiac arrest or
sudden cardiac death (6.33 [3.69–10.85]), heart failure (4.31, [3.30–5.62]), and atrial fibrilla-
tion (3.80 [3.04–4.75]). HCM was also associated with a higher incidence of myocardial
infarction ([MI] 1.90 [1.27–2.84]) and coronary revascularisation (2.32 [1.46–3.69]).The
absolute Kaplan-Meier risks at 3 years were 8.8% for the composite endpoint of cardiovas-
cular death or heart failure, 8.4% for the composite of cardiovascular death, stroke or myo-
cardial infarction, and 1.5% for major bleeding.
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Conclusions
Our study identified major unmet need in HCM and highlighted the importance of implement-
ing improved cardiovascular prevention strategies to increase life-expectancy of the con-
temporary HCM population. They also show that national electronic health records provide
an effective method for identifying outcomes and clinically relevant estimates of composite
efficacy and safety endpoints essential for trial design in rare diseases.
Introduction
With an estimated prevalence of 0.2% in young adults[1], hypertrophic cardiomyopathy
(HCM) is the most common genetic disorder of the cardiac muscle. This genetic disorder is
associated with premature death from sudden ventricular arrhythmia, heart failure and stroke
[2,3].
Estimating the long-term health burden of rare diseases such as HCM through retrospective
cohort studies and registries is difficult given the small number of people affected by the condi-
tions. This gap in evidence is one reason for a failure to conduct randomised trials powered to
detect clinically meaningful endpoints in HCM. In this study we hypothesised that popula-
tion-based electronic health records (EHR) can be used to identify the extent of unmet clinical
need in people with rare diseases such as HCM and thereby determine relevant outcome and
safety endpoints for use in trials.
By using the ClinicAl research using LInked Bespoke studies and Electronic health Records
(CALIBER) resource, which has been extensively validated in studies of cardiovascular risk
factors[4–10], myocardial infarction (MI)[11], and heart failure (HF)[12] in England, we
sought to develop an algorithm for the identification of cases of HCM and use it to provide
data on clinically relevant endpoints and potential trial safety measures.
Methods
Study population
We evaluated 5.37 million people’s records from 225 general practices in England providing
data to the CALIBER platform (Figure A in S1 File). CALIBER links individual EHR across
four data sources–primary care from the Clinical Practice Research Datalink (CPRD)[13]
coded with the Read system (which maps to the Systematized Nomenclacture of Medicine–
Clinical Terms, SNOMED-CT[14]); hospital data from the Myocardial Ischaemia National
Audit Project disease registry[15] and the Hospital Episodes Statistics; and the national death
registry (both coded with the International Classification of Diseases, ICD-10). The primary
care practices in CPRD are representative of the UK primary care setting[16,17] and patients
are representative of the general population in terms of age, sex, ethnicity[17,18] and overall
mortality[19]. Both cardiovascular endpoints and risk factors have been validated for epidemi-
ological research [4,6–9].
People with HCM
The approach to defining HCM in linked EHRs follows previously published methods for MI,
HF, atrial fibrillation (AF), rheumatoid arthritis or polymyalgia rheumatica[5,11,12,20,21] All
patients with HCM, registered in the general practices contributing data to CALIBER[22]
between January 1997 and March 2010 were identified. Those who had less than one year of
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follow-up after practice registration were excluded. HCM was defined based on codes for diag-
nosis and invasive therapy for left ventricular outflow tract obstruction in EHR from primary
care (Read codes) and hospital admissions (ICD-10 and OPCS codes; Fig 1). Additional infor-
mation was extracted to conduct sensitivity analyses to indirectly assess the validity of our defi-
nition of HCM by examining the robustness of estimates after restricting the analyses to
patients who had supporting information of HCM diagnosis. This information included: fam-
ily history of HCM (n = 60), cardiac arrhythmia (n = 244); surgical interventions (n = 153),
symptoms (n = 138) or medication (n = 390) recorded within 6 months of HCM diagnosis; a
referral to a cardiologist in the 6 months before HCM diagnosis (n = 8); and capture of HCM
diagnosis in both primary care and hospital (n = 331).
General population controls without HCM
Each individual with HCM was matched to up to ten randomly selected people without HCM
identified amongst those actively registered in the same general practice on his/her date of
inclusion (index date). HCM and non-HCM individuals were matched for age (±5 years) and
sex, and had a minimum of one year of follow-up after practice registration. People with
Fig 1. Defining cases of hypertrophic cardiomyopathy and non hypertrophic cardiomyopathy in national samples of structured electronic health records:
phenotype algorithm using multiple ontologies (ICD-10, Read-2, OPCS-4, BNF). [Fig note: The phenotype algorithm uses multiple ontologies: the International
Classification of Disease version 10 (ICD-10), the Read classification system, the Office of Population Censuses and Surveys Classification of Intervention and Procedures
(OPCS) and the British National Formulary (BNF). Grey shaded areas indicate how the algorithm was constructed for the definition of hypertrophic cardiomyopathy
(HCM) in primary analysis. Record of symptoms, cardiologist care, cardiac arrhythmia, medication and/or surgery within +/-6 months of a recorded HCM diagnosis was
considered evidence of supporting information of HCM. HA, hospital admissions; PC, primary care.].
https://doi.org/10.1371/journal.pone.0191214.g001
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diagnosis of other cardiomyopathies were excluded from the non-HCM comparison group.
Prior to the start of the study, it was estimated that including 12,760 individuals (1160 patients
with HCM and 10 randomly selected patients without HCM per exposed individual), and
assuming 80% power, a 2-sided 5% significance level and 10% probability of a cardiovascular
endpoint, would allow detecting a minimum effect size of 1.17 in a Cox Proportional Hazard
analysis (Stata/MP 13.1).
Risk factors, co-morbidities and treatments
Described patient characteristics recorded in primary care were: sex, age, index of multiple
deprivation, ethnicity, personal and family history of cardiomyopathy, cardiovascular risk fac-
tors (smoking status, diagnosis of diabetes mellitus, hypertension, systolic blood pressure,
body mass index, and serum lipids), and prescribed medication (blood pressure lowering med-
ication, statins, anticoagulant and antiplatelet drugs). Baseline characteristics were defined as
the most recent information recorded in primary care up to one year before study entry, a
diagnosis recorded at any time before or on the date of entry, or the recording of2 drug pre-
scriptions in the previous year. Hypertension was defined as a diagnosis recorded at any time
before or on the date of entry, or a minimum of 3 measurements of raised systolic or diastolic
blood pressure in the year prior to the date of study entry. Raised systolic blood pressure was
defined as140 mmHg (130 mmHg for patients with diabetes). Raised diastolic blood pres-
sure was defined as90 mmHg (80 mmHg for patients with diabetes). Definitions can be
found at https://www.caliberresearch.org/portal/.
Endpoints
We evaluated four groups of fatal and non-fatal disease endpoints. First, disorders which are
known to be strongly associated with HCM, and which constitute a validity check of the dis-
ease definition. These include cardiac arrest or sudden cardiac death (CA-SCD), ventricular
arrhythmia, AF, stroke and HF. Second, individual cardiovascular diseases where the evidence
that HCM is associated with an increased risk is less clear. These include coronary endpoints,
peripheral arterial disease (PAD), abdominal aortic aneurysm and a composite of deep venous
thrombosis and pulmonary embolism (DVT-PE). Third, we evaluated plausible composites
that could be/have been the basis of primary endpoints in clinical trials, including: all-cause
mortality, and cardiovascular mortality, MI and stroke. Fourth, we evaluated gastrointestinal
and major bleeding as potential trial safety endpoints. Definition of major bleeding was a
bleeding cause of death in the death registry or all cause death within 7 days of a bleeding
record in primary care or hospital admission, a hospital admission for 14 days or more or a
transfusion record in primary or hospital care within 30 days of a bleeding record. Sites of
major bleeding considered were intracranial, gastrointestinal, respiratory and ocular. Diagno-
sis codes used to define each endpoint can be found in Table A in S1 File.
Study design and follow-up period
All (100%) eligible individuals contributed follow-up information to the cohort study. For peo-
ple with HCM follow-up began on the date of first recorded HCM diagnosis (or date of the
invasive therapy for left ventricular outflow tract obstruction for HCM patients without
recorded HCM diagnosis) or on the date on which the patient was eligible for inclusion, if the
diagnosis was recorded earlier. For people without HCM the follow-up began on the index
date of the matched HCM patient. For individuals with and without HCM, the follow-up
ended on the first occurrence of the following: death, reaching a cardiovascular or bleeding
endpoint, or leaving (de-registering) from their general practice.
Unmet clinical need in hypertrophic cardiomyopathy
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Statistical analysis
We used descriptive statistics (mean and standard deviation [SD] or median and interquartile
range [IQR], as appropriate for continuous variables; and frequencies and percentages for cat-
egorical variables) to describe baseline individual characteristics and the frequency of any of
the morbidity endpoints recorded before study entry (history of cardiovascular endpoints) in
people with and without HCM.
To identify unmet clinical need in the HCM population, we compared incidence rates
for each endpoint using random-effects Poisson models with 95% confidence intervals (CI).
Poisson models were used instead of proportional hazard Cox models because the survival
curves for people with HCM and without HCM had hazard functions for several of the studied
outcomes that were not proportional over time. Within practice correlation was modelled
by applying random effects and allowing for clustering within practices. Models were adjusted
for established cardiovascular risk factors, including sex, age (linear and quadratic linear
terms), quintiles of index of multiple deprivation, smoking status, diabetes and systolic blood
pressure (linear term). Missing covariate data were handled using multiple imputation by
chained equations (Text A in S1 File). In secondary analyses, we tested whether associations
between HCM and study endpoints differed by sex, hypertension status at entry and the geo-
graphical location of the practice, using likelihood ratio tests for interaction. We also described
the causes of death in people with and without HCM. The following sensitivity analyses were
performed to assess the robustness of the findings to changes in the study definitions: i) exclu-
sion of people with diagnosed with HCM and other cardiomyopathies; ii) restriction to people
with HCM who had recorded supporting information for diagnosis; iii) comparison of esti-
mates according to the source of HCM diagnosis (exclusively in primary care vs. hospital
admissions; Fig 2).
Fig 2. Capture of hypertrophic cardiomyopathy diagnosis in hospital admissions, primary care or both in a national sample of 5,372,790 people.
https://doi.org/10.1371/journal.pone.0191214.g002
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Third, to provide data relevant to trial design, we estimated the incident rates of first occur-
ring endpoint (regardless of other endpoints) during the time of follow-up per 1000 person-
years and the 3-year Kaplan-Meier cumulative estimates with 95%CIs.
Analyses were done in Stata version 13.1 (StataCorp, College Station, Texas). Statistical sig-
nificance was defined as P<0.05.
Ethics
Approval was granted by the Independent Scientific Advisory Committee of the Medicines
and Healthcare Products Regulatory Agency and the MINAP Academic Group (Number
13_096R) and the MINAP Academic Group. The study was registered at clinicaltrials.gov
(trial registration NCT02424994). Access to de-identified data for authorised researchers is
provided within the UCL data safe haven. Linked CALIBER data (primary care data, Hospital
Episode Statistics and Office for National Statistics mortality data) were obtained from the
Clinical Practice Research Datalink (www.cprd.com). Access to de-identified data is only avail-
able once approval has been obtained through the individual constituent entities controlling
access to the data (https://www.cprd.com/dataAccess/). The phenotype algorithms described
in this paper are shown in the Supporting Information (Table 1 in S1 File) and are also freely
available via the CALIBER website at www.caliberresearch.org and the CALIBER data portal is
available for consultation online at http://www.caliberresearch.org.
Results
Patient characteristics
We identified 1,375 cases of HCM among the 3,3 million eligible CALIBER patients (4 per
10,000). In total 1,160 people with HCM and 11,304 individuals without HCM (10 matches for
each of 864 and 9 for each of the remaining 296 individuals without HCM) were included in
the analysis. Median age at first recorded diagnosis was 57 years [IQR 43–70] and 40.9% were
women (Table 1). Median duration since registration in the general practice was 11.6 years. At
the time of diagnosis, or within the preceding year, 17.8% received statins, 53.9% blood pres-
sure lowering medication, 9.0% anticoagulant drugs (23.9% of patients with history of AF
received warfarin) and 8.7% amiodarone. Mean systolic blood pressure was similar in people
with and without HCM but higher proportions of individuals with HCM had recorded history
of co-existing cardiovascular disease at the time of HCM diagnosis (47.2% vs. 2.5%). The most
common cardiovascular diseases recorded before the study entry among people with HCM
were stable angina (24.3%), AF (16.1%) and HF (12.8%).
Unmet clinical need: Relative incidence of fatal and non-fatal endpoints in
HCM vs controls
Overall, individuals contributed 62,856.8 person-years of follow-up, median of 4.0 years. As
expected, compared to people without HCM, individuals with HCM had much higher inci-
dence of CA-SCD (adjusted IRR = 6.33, 3.69–10.85), ventricular arrhythmia (IRR = 23.53,
95%CI 12.67–43.72), AF (IRR = 3.80, 95%CI 3.04–4.75), stroke (IRR = 2.13, 95%CI 1.53–2.97)
and HF (IRR = 4.31, 3.30–5.62; Fig 3). People with HCM had also increased incidence of
recorded coronary and PAD and of cardiovascular composite endpoints. In particular people
with HCM had higher incidence of MI (IRR = 1.90, 95%CI 1.27–2.84), coronary revascularisa-
tion (IRR = 2.32, 95%CI 1.46–3.69), and a composite of cardiovascular death, stroke or MI
(IRR = 2.50, 95%CI 1.77–3.52) No evidence of interaction by sex was found except for PAD
(IRR = 1.54, 95%CI 0.73–3.22 for men; IRR = 4.51, 95%CI 2.43–8.38 for women; interaction
Unmet clinical need in hypertrophic cardiomyopathy
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Table 1. Characteristics of a national sample of people with and without hypertrophic cardiomyopathy.
People with HCM (n = 1,160) People without HCM (n = 11,304)
Sociodemographic factors
Age in years, mean (SD) 55.8 (19.9) 54.9 (19.6)
Women, n (%) 476 (41.0) 4,620 (40.9)
Index of multiple deprivation in quintiles, n (%)
1 (least deprived) 225 (19.5) 2,261 (20.1)
5 (most deprived) 248 (21.5) 2,232 (19.8)
Ethnicity, n (%)
White 756 (91.3) 5,387 (91.8)
Asian 43 (5.2) 209 (3.6)
Afro-Caribbean 19 (2.3) 157 (2.7)
Other 10 (1.2) 113 (1.9)
Geographical location of GP practices, n (%)
North England 231 (19.9) 2280 (20.1)
East Midlands and West England 317 (27.3) 317 (27.0)
London and South England 612 (52.8) 612 (52.9)
Duration of registration in years, median [IQR] 9.7 [2.3–18.8] 11.8 [5.4–21.3]
No. of consultations in previous year 7 [3–12] 4 [1–7]
No. of hospitalisation in previous year 0 [0–1] 0 [0–0]
Personal and family history of cardiac disease
Congenital cardiomyopathy, n (%) 6 (0.5) -
Other cardiomyopathies, n (%) 85 (7.3) -
History of any prior CVDa, n (%) 548 (47.2) 294 (2.6)
Cardiovascular risk factors
Smoking, n (%)
Current 9 (12.7) 1,050 (13.0)
Former 22 (31.0) 1,961 (24.3)
Never 40 (56.3) 5,067 (62.7)
Diabetes 74 (6.4) 564 (5.0)
Hypertension 696 (60.0) 5,647 (50.0)
Systolic blood pressure in mmHg, mean (SD) 136 (21.3) 139 (18.6)
Body mass index in kg/m2, mean (SD) 27.3 (5.2) 27.7 (5.7)
Total cholesterol in mmol/L, mean (SD) 5.0 (1.2) 5.3 (1.1)
HDL cholesterol in mmol/L, mean (SD) 1.3 (0.4) 1.4 (0.4)
LDL cholesterol in mmol/L, mean (SD) 2.8 (1.0) 3.1 (1.0)
Triglycerides in mmol/L, mean (SD) 1.6 (0.8) 1.6 (0.9)
Serum creatinine in mg/L, mean (SD) 98.2 (32.5) 89.4 (21.1)
Medication use in previous year
Any blood pressure lowering medication, n (%) 625 (53.9) 2,624 (23.2)
Beta-blockers 117 (10.1) 67 (0.6)
Calcium antagonists 115 (9.9) 66 (0.6)
ACEI/ARBs 276 (23.8) 1166 (10.3)
Amiodarone, n (%) 97 (8.4) 9 (0.1)
Statins, n (%) 206 (17.8) 747 (6.6)
Antiplatelet drug, n (%) 269 (23.2) 609 (5.4)
Aspirin, n (%) 255 (22.0) 598 (5.3)
(Continued)
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p-value = 0.03; Figure B in S1 File). Rate ratios were similar regardless of the geographical loca-
tion of the general practice (Figure C in S1 File). However, higher estimates were generally
observed in people without hypertension than amongst those with hypertension at baseline
(Figure D in S1 File). The median age at endpoint occurrence was lower for people with HCM
except for PAD and DVT-PE. Larger differences in the age at presentation compared to people
without HCM were observed for cardiac arrest and ventricular arrhythmias (26 and 12 years,
respectively).
Absolute risk of plausible composite efficacy and safety endpoints
Incidence rates and 3-year Kaplan-Meier estimates for key clinical and safety endpoints rele-
vant for trial design are shown in Table 2. Cumulative endpoint estimates among people with
HCM at 3 years were 6.7% for HF, 8.8% for a composite of cardiovascular death or HF and
8.4% for a composite of cardiovascular death, stroke or MI. Estimates for trial safety endpoints
were 1.5% for major bleeding and 6.0% for gastrointestinal bleeding. The most common
coded clinical presentations in people with HCM but no prior history of cardiovascular end-
points were AF, HF and coronary heart disease (Figure E in S1 File).
Unmet clinical need: HCM and cause specific mortality
A total of 1,597 deaths were recorded during follow-up, 275 (23.7%) in people with HCM and
1,322 (11.7%) in non-HCM patients. Sixty-two percent of people with a recorded cause of
death (n = 1,550) died of non-cardiovascular death (44.5% and 67.5% in the HCM and non-
HCM groups, respectively; Figure F in S1 File). All-cause and cardiovascular mortality rates
were higher in people with HCM, with ratios of 2.05 (95%CI 1.60–2.63) for all-cause and 2.28
(95%CI 1.93–2.69) for cardiovascular death. However, no differences in mortality rates
between people with and without HCM were observed for non-cardiovascular death (IRR =
0.88, 95% 0.69–1.11). Diseases of the myocardium and ischaemic heart diseases were the most
common recorded causes of cardiovascular death in people with HCM (Figure G in S1 File).
No evidence of difference in rates of fatal CA-SCD, HF or stroke was found between people
with or without HCM. However, fatal MI was higher in people with HCM (IRR = 4.31, 95%CI
1.69–11.03). Estimates of associations between HCM and fatal endpoints did not differ by sex,
hypertension status or the geographical location of the general practice.
Sensitivity analyses
Results were robust to sensitivity analyses excluding people with HCM who had other cardio-
myopathies diagnosed (n = 91), when restricted to people with HCM and supporting informa-
tion of HCM (n = 690) and in people with HCM who had diagnosis exclusively recorded in
primary care or in hospital (Figures H and I in S1 File).
Table 1. (Continued)
People with HCM (n = 1,160) People without HCM (n = 11,304)
Anticoagulant drug, n (%) 104 (9.0) 88 (0.8)
Note: HCM, hypertrophic cardiomyopathy; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SD, standard deviation. Missing data (%): index of multiple
deprivation 0.4%; ethnic group 46.3%; body mass index 42.8%; systolic blood pressure 19.9%; serum c-reactive protein 56.7%; smoking 28.3%; total cholesterol 64.6%;
HDL cholesterol 73.4%; LDL cholesterol 77.1%; triglycerides 72.5%; serum creatinine 56.7%.
aHistory of CVD included record of previous episodes of any of the 14 cardiovascular endpoints investigated.
https://doi.org/10.1371/journal.pone.0191214.t001
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Discussion
We examined a national sample of population-based EHRs for 3 million individuals and made
three novel findings. First, we demonstrate a methodology for using structured national EHRs
Fig 3. Relative risks (95% CI) of fatal and non-fatal clinically relevant and trial safety endpoints in a national sample of people with hypertrophic cardiomyopathy
(vs. no hypertrophic cardiomyopathy). [Fig note: CI, confidence interval; DVT, deep vein thrombosis; MI, myocardial infarction; IRR, incidence rate ratios from
random effects Poisson models adjusted for age, sex, index of multiple deprivation, smoking status, diabetes and systolic blood pressure; PE, pulmonary embolism; SCD,
sudden cardiac death.].
https://doi.org/10.1371/journal.pone.0191214.g003
Unmet clinical need in hypertrophic cardiomyopathy
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Table 2. Incidence rates of endpoints and 3-year Kaplan-Meier estimates in a national sample of people with and without hypertrophic cardiomyopathy.
People with HCM
N = 1,160
People without HCM
N = 11,304
No. of incident
events
Rate / 1000 PY
(95% CI)
3 year Kaplan-Meier
estimates as %
(95% CI)
No. of incident
events
Rate / 1000 PY
(95% CI)
3 year Kaplan-Meier
estimates as %
(95% CI)
Endpoints with known
association
Ventricular arrhythmia 39 8.32 (6.09–
11.40)
2.27 (1.42–3.61) 18 0.31 (0.20–
0.49)
0.08 (0.04–0.17)
Cardiac arrest or SCD 34 7.18 (5.13–
10.05)
2.15 (1.33–3.46) 56 0.97 (0.74–
1.26)
0.23 (0.15–0.35)
Atrial fibrillation 133 35.12 (29.63–
41.62)
9.41 (7.41–11.92) 488 8.70 (7.96–
9.50)
2.31 (2.02–2.65)
Heart failure 103 25.29 (20.85–
30.68)
6.67 (5.00–8.87) 367 6.43 (5.80–
7.12)
1.84 (1.58–2.15)
Transient ischaemic attack 27 5.87 (4.03–
8.57)
2.03 (1.22–3.37) 155 2.70 (2.31–
3.16)
0.78 (0.62–0.99)
Stroke 52 11.24 (8.56–
14.75)
2.81 (1.83–4.31) 324 5.66 (5.08–
6.31)
1.56 (1.32–1.84)
Endpoints with lack of previous evidence
Stable angina 83 25.40 (20.48–
31.50)
8.93 (6.86–11.59) 449 8.01 (7.31–
8.79)
2.48 (2.17–2.83)
Unstable angina 44 9.95 (7.41–
13.38)
2.61 (1.66–4.09) 158 2.75 (2.36–
3.22)
0.81 (0.64–1.03)
Myocardial infarction 44 9.93 (7.39–
13.34)
2.29 (1.40–3.74) 276 4.82 (4.28–
5.42)
1.34 (1.12–1.61)
Coronary heart disease NOS 120 34.48 (28.83–
41.24)
9.88 (7.74–12.57) 617 10.93 (10.10–
11.83)
2.83 (1.50–3.20)
Unheralded coronary death 13 2.67 (1.55–
4.59)
1.10 (0.54–2.20) 133 2.30 (1.94–
2.72)
0.64 (0.49–0.83)
Coronary revascularisation 32 6.86 (4.85–
9.70)
1.84 (1.11–3.06) 170 2.96 (2.55–
3.44)
0.77 (0.61–0.98)
Peripheral arterial disease 28 5.95 (4.11–
8.62)
1.50 (0.83–2.71) 147 2.56 (2.18–
3.01)
0.65 (0.50–0.84)
Abdominal aortic aneurysm 10 2.07 (1.11–
3.85)
0.25 (0.06–1.00) 64 1.11 (0.87–
1.42)
0.24 (0.16–0.37)
DVT or PE 24 5.10 (3.42–
7.61)
0.89 (0.71–1.11) 206 3.63 (3.17–
4.17)
2.27 (1.42–3.61)
Plausible trial composites
All cause death 239 49.12 (43.27–
55.76)
14.16 (11.98–16.70) 1,307 22.59 (21.40–
23.85)
5.83 (5.37–6.34)
CVD death, stroke or MI 115 26.25 (21.86–
31.51)
8.38 (6.58–10.64) 496 8.70 (7.97–
9.50)
2.40 (2.09–2.74)
CVD death or heart failure 110 27.06 (22.45–
32.62)
8.78 (6.86–11.21) 516 9.04 (8.29–
9.85)
2.46 (2.16–2.81)
Transient ischaemic attack or
stroke
67 15.10 (11.89–
19.19)
4.14 (2.90–5.90) 430 7.56 (6.88–
8.31)
2.12 (1.83–2.44)
Non-cardiovascular death 109 22.39 (18.56–
27.01)
6.63 (5.11–8.59) 859 14.84 (13.89–
15.87)
3.87 (3.48–4.29)
Trial safety endpoints
Major bleeding 20 4.12 (2.66–
6.39)
1.47 (0.83–2.59) 92 1.59 (1.30–
1.95)
0.39 (0.28–0.55)
(Continued)
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in ambulatory (primary) care and hospital practice that provides the basis of a national quality
and outcome registry for rare disease adaptable for use in other countries. Second, despite
modern management guidelines, there is major unmet clinical need in patients with HCM
illustrated by a substantial excess of preventable fatal and non-fatal endpoints including HF,
AF and thromboembolism. Third, we provide accurate risk estimates of composite efficacy
and safety endpoints to inform future trial design in this disease.
We chose to study HCM as–despite the fact that it is uncommon–it is a potentially fatal
inheritable disease amenable to therapeutic intervention. The novelties of this study are the
record-linkage cohort design, the comparison with a population-based group of people without
HCM, its contemporaneity, and the investigation of fatal and non-fatal cardiovascular endpoints
that have been validated in the CALIBER dataset[4,6–11]. The longitudinal design and the anal-
ysis of patient linked EHRs covering primary, hospital and mortality data allowed the identifica-
tion of a matched comparison group selected from the same population. They also permitted
ascertainment of HCM status regardless of disease severity and level of care management (note
many patients were managed in ambulatory care and not hospitalised with their HCM).
We developed the first phenotype algorithm for HCM to identify people diagnosed with
this disease using national structured EHR based on codes for diagnosis, procedures and
drugs. While there are some limitations inherent in using national data for this specific dis-
ease–for example, a lack of corroborative echocardiographic imaging and genetic testing or
the under-recording of information about family history of the disease (i.e. only recorded for
5% of people with HCM)–the HCM algorithm is transferrable to other countries which use
SNOMED-CT and ICD-10 or similar ontologies[23]. A diagnosis of HCM is sufficiently spe-
cific that it is likely to be used only where the index of clinical suspicion is high. In addition,
the very high relative and absolute risk of ventricular arrhythmia, CA-SCD and HF observed
in patients with HCM is strong evidence of the diagnostic validity of the EHR algorithm. We
nevertheless cannot however completely rule out the misclassification of a minority of patients
wrongly labelled as diagnosed with HCM with clinical characteristics similar to HCM (e.g.
patients with hypertension related enlargement of ventricles [24]). Indeed, 60% of people with
HCM in our study were considered to have hypertension, which we defined as a recorded
diagnosis of hypertension or a minimum of 3 high blood pressure readings recorded in the
year prior to data entry. The proportion of people with HCM who had a recorded diagnosis of
hypertension in our cohort was of 50%. This proportion is only slightly higher than estimates
reported in previous studies (46–47% [25,26]). Unfortunately, in our data it is not possible to
determine what patients were diagnosed and/or regularly treated by cardiologists.
This is the first study to determine the incidence of a wide range of fatal and non-fatal car-
diovascular endpoints in people with HCM compared to random sample of individuals
Table 2. (Continued)
People with HCM
N = 1,160
People without HCM
N = 11,304
No. of incident
events
Rate / 1000 PY
(95% CI)
3 year Kaplan-Meier
estimates as %
(95% CI)
No. of incident
events
Rate / 1000 PY
(95% CI)
3 year Kaplan-Meier
estimates as %
(95% CI)
Gastrointestinal bleeding 91 21.84 (17.79–
26.83)
5.99 (4.47–7.99) 589 11.04 (10.18–
11.97)
3.08 (2.72–3.48)
Note: CI, confidence interval; CVD, cardiovascular disease; DVT, deep vein thrombosis; HCM, hypertrophic cardiomyopathy; MI, myocardial infarction; PE,
pulmonary embolism; SCD, sudden cardiac death. Non-disease estimates are obtained among up to 10 randomly selected patients without hypertrophic
cardiomyopathy matched for sex, age, medical practice and index date; PY, person-years of follow-up.
https://doi.org/10.1371/journal.pone.0191214.t002
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without the disease drawn from the general population. Contemporary outcome studies from
specialist referral centres suggest that the prognosis of managed cohorts is relatively benign in
terms of life expectancy[27,28]. However, this analysis of national EHRs suggests that there is,
instead, a substantial unmet need with respect to the risk of complications that associates with
a poorer long-term survival compared to the normal population. The risk of some of these
complications–for example, sudden cardiac death and stroke–may be lowered if existing prac-
tice guidelines are implemented. We provide evidence that current clinical guidelines for
HCM are not being followed. For example, more than a quarter of patients with HCM and AF
were not treated with anticoagulants in spite of clear recommendations in practice guidelines
to do so. Similarly, the high incidence of CA-SCD suggests that risk stratification and prophy-
lactic implantable cardioverter defibrillators are underutilised.
Unexpectedly, we found that people with HCM were at higher risk of MI and coronary
revascularisation compared to population controls. This novel finding is difficult to explain
with our current understanding of the pathophysiology of HCM. It might result from misdiag-
nosis in patients with elevated serum troponin levels in the presence of angiographically nor-
mal coronary arteries[29], but this does not explain the small but significant coronary
revascularisation excess. People with HCM were also more likely to be prescribed statins and
antiplatelets than population controls; but again this may be explained not by an excess of ath-
erosclerotic disease but rather by the indiscriminate use of secondary prevention in symptom-
atic people with HCM. This latter point is not trivial as patients with HCM may be exposed
unnecessarily to polypharmacy and side-effects such as bleeding.
With respect to the second aim of this study, future trial design, we provide data that can
be used to estimate sample size and the length of treatment required to power randomised
interventions targeting specific endpoints such as stroke, progressive HF and ventricular
arrhythmia. For the first time, we examine a specific safety endpoint–bleeding risk–in compar-
ison to a normal matched population. This will be of particular interest in trials designed to
reduce the high rate of thromboembolism seen in this study. Finally, these same primary care
data are a potential route back to patients, in that they can be contacted for randomization via
CPRD.
More broadly this study has implications for the approach to other uncommon and rare
diseases. Deep, computable efforts at characterizing and annotating phenotype algorithms in
rare diseases have used the human phenotype ontology (HPO). It is possible to map 92% of the
10,454 HPO concepts to SNOMED CT (30% complete mapping and 62% partial) suggesting
the potential of power of national EHR to identify and perform unbiased analysis of much
rarer conditions that are otherwise very difficult to study[23]. For example, the CPRD, which
provided the primary care data in this study, also provides services to randomise patients at
the point of care[30].
Potential limitations not already discussed include the possibility that temporal or provider
changes in clinical diagnosis and management of patients might affect differences in incidence
of endpoints between HCM and non-HCM patients. However, the matching design for prac-
tice and date of study inclusion minimised the likelihood of this type of bias. We were also
unable to distinguish between people with or without left ventricular hypertrophy and the
large number of missing baseline lipid values prevented adjustment of ratios for this cardiovas-
cular risk factor.
In summary, this study identified major unmet clinical need in HCM and highlights the
importance of implementing improved cardiovascular prevention strategies that increase the
life-expectancy of people with HCM. It also provided clinically meaningful risks of safety and
composite efficacy endpoints essential for trial design, demonstrating the value of national
EHR in bringing treatment trials to rare and uncommon diseases.
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